Research graph
References from Effects of Repeated Ketamine Infusions on Suicidal Ideation in Treatment-Resistant Depression and Associated Changes in Selected Plasma Biomarkers. Local targets link to admitted publications; unresolved targets remain external evidence.
Depression is the leading cause of disability around the world
10.1001/jama.2017.3826 · 2017 · External reference
Suicide prevention strategies: a systematic review
10.1001/jama.294.16.2064 · 2005 · External reference
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
10.1038/s41380-018-0256-5 · 2020 · External reference
Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: a retrospective chart review
10.1016/j.jad.2020.07.089 · 2020 · External reference
Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis
10.1016/j.jpsychires.2022.04.037 · 2022 · External reference
Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial
10.1136/bmj-2021-067194 · 2022 · External reference
Ketamine vs midazolam: mood improvement reduces suicidal ideation in depression
10.1016/j.jad.2021.12.055 · 2022 · External reference
Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients: a multicenter pilot analysis
10.1371/journal.pone.0165267 · 2016 · External reference
Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis
10.1038/s41380-022-01652-1 · 2022 · External reference
Acute and long-term effects of repeated ketamine infusions in treatment-resistant depression and associated metabolite changes
10.1111/pcn.13870 · 2025 · External reference
A new depression scale designed to be sensitive to change
10.1192/bjp.134.4.382 · 1979 · External reference
The columbia–suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults
10.1176/appi.ajp.2011.10111704 · 2011 · External reference
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
10.1016/s0006-3223(03)01866-8 · 2003 · External reference
Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: an exploratory pilot case-control study
10.1016/j.jad.2018.01.014 · 2018 · External reference
Personality classification enhances blood metabolome analysis and biotyping for major depressive disorders: two-species investigation
10.1016/j.jad.2020.09.118 · 2021 · External reference
Defining pathological social withdrawal: proposed diagnostic criteria for hikikomori
10.1002/wps.20705 · 2020 · External reference
The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis
10.1176/appi.ajp.2017.17040472 · 2018 · External reference
Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression
10.1038/s41386-019-0570-x · 2020 · External reference
The kynurenine pathway: a finger in every pie
10.1038/s41380-019-0414-4 · 2020 · External reference
Ketamine’s effect on inflammation and kynurenine pathway in depression: a systematic review
10.1177/02698811211026426 · 2021 · External reference
Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression
10.1016/j.bbi.2026.106889 · 2026 · External reference
Mitochondria in depression: the dysfunction of mitochondrial energy metabolism and quality control systems
10.1111/cns.14576 · 2024 · External reference
Ketamine’s antidepressant effect is mediated by energy metabolism and antioxidant defense system
10.1038/s41598-017-16183-x · 2017 · External reference
